Christine Ambrosone
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Risk factors and molecular mechanisms for estrogen receptor negative breast cancer
Open Date: 2024-10-01
Close Date: 2025-09-30
Grant: Close
Risk factors and molecular mechanisms for ER negative breast cancer
Open Date: 2017-10-01
Close Date: 2018-09-30
Grant: Close
Cell-mediated Immunity and quality of life in breast cancer patients: a longitudinal study
Open Date: 2014-10-01
Close Date: 2015-09-30
Grant: Close
Cell-mediated immunity and quality-of-life in breast cancer patients: A Longitudinal Study
Open Date: 2012-07-24
Close Date: 2018-02-22
Grant: Close
Basal-like Breast Cancers in Black and White Women: an 'Out of Africa' Hypothesis
Open Date: 2010-07-30
Close Date: 2018-02-22
Articles (48)
Background: Research has linked neighborhood factors (e.g., air pollution, obesogenic environment) often associated with residential segregation to cancer disparities, including mortality. Limited research has explored these multilevel drivers of health, recognizing residential segregation as upstream of neighborhood social, built, and physical environment attributes. In this study, we describe the neighborhood data resource of the Pathways Study, a diverse cohort of women diagnosed with breast cancer. Methods: Using data from multiple sources, including the 2010 US Census, we appended census tract and block group-level measures that characterize the participants’ baseline neighborhoods. We examined distributions of neighborhood attributes by the Index of Concentration at the Extremes, a measure of racialized economic segregation, to demonstrate the relationships among these factors. Results: Twenty-eight percent of the participants resided in neighborhoods with the highest concentrations of high-income non-Hispanic White residents [i.e., most privileged neighborhoods; quintile (Q) 5] compared with only 9% who resided in neighborhoods with the highest concentrations of low-income residents from minoritized racial/ethnic groups (i.e., least privileged neighborhoods, Q1). Participants residing in less privileged neighborhoods had more exposure to detrimental neighborhood attributes, including a higher overall pollution burden, markers of physical disorder (e.g., graffiti and garbage), more barred windows, and a higher crime index. Conclusions: For a cohort of breast cancer survivors, residing in neighborhoods with less privilege shows evidence of adverse neighborhood attributes across domains of social, built, and physical environments. Impact: This neighborhood infrastructure is well positioned to assess interactions across the multilevel factors contributing to health disparities in women with breast cancer.
Year:
2026
Background: Research has linked neighborhood factors (e.g., air pollution, obesogenic environment) often associated with residential segregation to cancer disparities, including mortality. Limited research has explored these multilevel drivers of health, recognizing residential segregation as upstream of neighborhood social, built, and physical environment attributes. In this study, we describe the neighborhood data resource of the Pathways Study, a diverse cohort of women diagnosed with breast cancer. Methods: Using data from multiple sources, including the 2010 US Census, we appended census tract and block group-level measures that characterize the participants’ baseline neighborhoods. We examined distributions of neighborhood attributes by the Index of Concentration at the Extremes, a measure of racialized economic segregation, to demonstrate the relationships among these factors. Results: Twenty-eight percent of the participants resided in neighborhoods with the highest concentrations of high-income non-Hispanic White residents [i.e., most privileged neighborhoods; quintile (Q) 5] compared with only 9% who resided in neighborhoods with the highest concentrations of low-income residents from minoritized racial/ethnic groups (i.e., least privileged neighborhoods, Q1). Participants residing in less privileged neighborhoods had more exposure to detrimental neighborhood attributes, including a higher overall pollution burden, markers of physical disorder (e.g., graffiti and garbage), more barred windows, and a higher crime index. Conclusions: For a cohort of breast cancer survivors, residing in neighborhoods with less privilege shows evidence of adverse neighborhood attributes across domains of social, built, and physical environments. Impact: This neighborhood infrastructure is well positioned to assess interactions across the multilevel factors contributing to health disparities in women with breast cancer.
Year:
2026
Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, and RAD51D) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort (n = 9,887), a population-based cohort (n = 3,876), and the UK Biobank (n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1, BRCA2, and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM, BRCA1, BRCA2, CHEK2, and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM, BRCA1, BRCA2, CHEK2, and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.
Year:
2025
Objective Having children reduces risk of breast cancer overall, but parity without breastfeeding, more prevalent among black women, increases risk of poor-prognosis oestrogen receptor negative (ER−) breast cancer. We investigated if relationships between parity, breastfeeding and ER subtypes result from epigenetic programming, potentially steering breast progenitor cells to a basal-like phenotype. Methods and analysis The Illumina MethylationEPIC platform was used to assess genome-wide methylation in formalin-fixed, paraffin-embedded tumours from 1459 Black women with breast cancer. Methylation was evaluated in relation to parity, breastfeeding and breast cancer subtypes in a case-only analysis, with methylation-gene expression pairs tested in a subset of cases. We then performed functional enrichment analysis for probes significantly associated with parity and breastfeeding. Results Among women who did not breastfeed (n=634), there were 500 significant (p<1e−5) differentially methylated loci (DML) by parity, compared with only five DMLs among women who had breastfed their children (n=568). One of the top DML genes was FOXA1 , pivotal in governing the luminal lineage of progenitor cells, with a statistically significant interaction (p=0.04) for number of births and breastfeeding. Associations were strongest for ER− disease. Conclusion In this large study of Black women with breast cancer, we elucidated biological pathways for the observed associations between parity without breastfeeding and breast cancer subtypes, revealing distinct molecular alterations in breast DNA, particularly for ER− tumours. Black women in the USA tend to have more children and are less likely to breastfeed; their breast cancer risk may be reduced by societal systems that promote and support breastfeeding.
Year:
2025
Hazard ratios (HR) and 95% confidence intervals (95% CI) for the association of 2-year post-diagnosis lifestyle with all-cause mortality, breast cancer-mortality, and breast cancer recurrence among women diagnosed with stage I–III breast cancer.
Year:
2025
Hazard Ratios and 95% Confidence Intervals for Associations of each of the 9 Components of the 2-Year Post-Diagnosis Lifestyle Score with All-Cause Mortality, Breast Cancer-Specific Mortality, and Breast Cancer Recurrence, Excluding Deaths and Recurrences Occurring within 4 Years of Diagnosis.
Year:
2025
Subdistribution hazard ratios (sdHR) and 95% confidence intervals (95% CI) for the association of 2-year post-diagnosis lifestyle with breast cancer-specific mortality (n=1,736) and breast cancer recurrence (n=1,705).
Year:
2025
Posterior Median Hazard Ratios and 95% Credible Intervals from Piecewise Exponential Proportional Hazards Model for All-Cause Mortality, Breast Cancer-Specific Mortality, and Breast Cancer Recurrence in the Pathways Study
Year:
2025
Interactions Between the 2-Year Post-Diagnosis Lifestyle score and Selected Characteristics with All-Cause Mortality, Breast Cancer-Specific Mortality, and Breast Cancer Recurrence in the Pathways Study.
Year:
2025
Cumulative incidence of all-cause mortality, breast cancer-specific mortality, and breast cancer recurrence among women diagnosed with invasive breast cancer in the Pathways Study, according to tertiles of the 2-year post-diagnosis lifestyle score, 2006–2018
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (107)
Montserrat Garcia-Closas
Professor of Epidemiology
Institute of Cancer Research
Tomáš Zima
Head of Institute
Charles University and General University Hospital in Prague, First Faculty of Medicine
Kathleen Claes
Full professor
Ghent University Hospital
Giuseppe Matullo
-
Pushkar Inamdar
University of California, San Francisco
Lisa Wiesmüller
Professor
Ulm University
Christopher A. Haiman
University of Southern California
Andriy Derkach
Associate Attending Biostatistician
Memorial Sloan Kettering Cancer Center
Lauren E. McCullough
-
Jennifer Hu
Professor
University of Miami
Eric Hahnen
-
Susan Domchek
Professor, Clinician-Educator
University of Pennsylvania
Sara Lindström
University of Washington
Maria Rossing
Associate Clinical Professor
Copenhagen University Hospital
Marco Montagna
Istituto Oncologico Veneto
Katherine Nathanson
Professor
University of Pennsylvania
Xiao‐Ou Shu
Vanderbilt University Medical Center
Nicoletta Resta
Full Professor Medical Genetics
University of Bari Aldo Moro
Song Yao
Professor
Roswell Park Comprehensive Cancer Center
Maria Piane
Sapienza University of Rome
Sara González
Institut Català d'Oncologia
Shiv Prakash Verma
Senior Research Scientist
Memorial Sloan Kettering Cancer Center
FEI CHEN
Assistant Professor
University of Southern California
Bo Qin
Associate Professor of Medicine
Rutgers Cancer Institute of New Jersey
Katie O'Brien
Staff Scientist
National Institute of Environmental Health Sciences
Scarlett L. Gomez
University of California, San Francisco
A Heather Eliassen
Professor
Harvard University
Qiang Hu
Roswell Park Comprehensive Cancer Center
Tanish Gandhi
Ohio State University
Lei Wei
Assistant Professor
Roswell Park Comprehensive Cancer Center
Alexandra Martins
INSERM
Stefan Ambs
Senior Investigator (tenured) and Head of the Molecular Epidemiology Section
National Cancer Institute
Dale Sandler
Branch Chief
National Institute of Environmental Health Sciences
Julie R Palmer
Boston University School of Medicine
Clarice Weinberg
Principal Investigator
National Institute of Environmental Health Sciences
Alexander E Volk
-
Weang Kee Ho
Professor
Sunway University
Wei Zheng
-
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Yara G Abdou
University of North Carolina at Chapel Hill
Kitaw Demissie
Dean and Professor
SUNY Downstate Health Sciences University School of Public Health
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
W. Dana Flanders
Professor
Rollins School of Public Health
Lindsay J Collin
Assistant Professor
Emory University
Mariarosaria Calvello
European Institute of Oncology
Mario Schootman
Professor
University of Arkansas for Medical Sciences
Qiuyin Cai
Professor
Vanderbilt University Medical Center
anna coppa
Sapienza University of Rome
Allison DePersia
NorthShore University HealthSystem
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Florentia Fostira
National Centre for Scientific Research-Demokritos
Paolo Radice
Head of Reserach Unit
Fondazione IRCCS Istituto Nazionale dei Tumori
Maria Elena. Martinez
University of California
Marketa Janatova
Assistanf Professor and researcher
Přírodovědecká Fakulta, Univerzita Karlova
Melissa A. Troester
Professor
University of North Carolina at Chapel Hill
John D. Carpten
City of Hope Comprehensive Cancer Center
Elad Ziv
Professor
University of California
GUOCHONG JIA
Vanderbilt University
Andrew Olshan
University of North Carolina at Chapel Hill
Gareth Evans
The University of Manchester
Esther John
Professor
Stanford University School of Medicine
Charles F. Lynch
-
Chi-Chen Hong
Associate Professor of Oncology
Roswell Park Comprehensive Cancer Center
Weng Khong Lim
Assistant Professor
Duke-NUS Medical School
Barbara Pasini
Associate Professor of Medical Genetics
Università degli Studi di Torino
Dezheng Huo
University of Chicago
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Gordon Watt
Junior Group Leader
The Netherlands Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Xingyi Guo
Associate Professor
Vanderbilt University Medical Center
Jeffrey Weitzel
Professor and Director
University of Kansas Cancer Center
Peggy Reynolds
Professor
University of California, San Francisco
Jirong Long
Professor
Vanderbilt University Medical Center
Julie Von Behren
University of California, San Francisco
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Andrew G. Rundle
Professor
-
Nereida Sotelo
Ohio State University
Paul Auer
Professor
Medical College of Wisconsin
Jo Freudenheim
SUNY Distinguished Professor and Associate Dean
University at Buffalo
Hoda Anton-Culver
Professor and Chair
University of California, Irvine
Amber Aeilts
Assistant Professor, Genetic Counselor
Ohio State University
Terryl Hartman
Professor
Emory University
Adana Llanos
Associate Professor, Tenured
Columbia University
Alvaro Monteiro
Senior Member - Full Professor
H Lee Moffitt Cancer Center and Research Institute
Yaohua Yang
Assistant Professor
University of Virginia
Corinna Ernst
Hannover Medical School
Salma Shariff‐Marco
Professor
University of California, San Francisco
Patrick Bradshaw
University of California, Berkeley
Allison W Kurian
Professor
Stanford University School of Medicine
Jian Gu
The University of Texas MD Anderson Cancer Center
Jesse J Plascak
co-Leader
Fred Hutchinson Cancer Research Center
Kathryn Ruddy
Professor
Mayo Clinic
Olufunmilayo I. Olopade
Professor
University of Chicago
Lidia Feliubadaló
Institut Català d'Oncologia
Christopher Li
Fred Hutchinson Cancer Research Center
Koichi Matsuda
University of Tokyo
Kimberly A. Bertrand
Associate Professor of Medicine
Boston University
Bingshan Li
Vanderbilt University
Joanne Ngeow
Head
Nanyang Technological University (NTU)
Eric Polley
Associate Professor
University of Chicago
Elisa Bandera
Chief
Rutgers Cancer Institute of New Jersey
Stephen Mooney
Associate Professor
University of Washington
Zdenek Kleibl
Laboratory of oncogenetics (head)
Charles University, First Faculty of Medicine
Nicholas Boddicker
Research Associate
Mayo Clinic
Amanda Toland
Ohio State University
Argyrios Ziogas
Professor
University of California, Irvine
Laura Cortesi
University of Modena and Reggio Emilia
Make your next move.
Prepare your application
Review drafts before you send them.